J B Chemicals & Pharmaceuticals Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7nve5ag5cdkslqs7gy0cqe5x.pdf

Key Takeaways


Domestic Business: Volume-Led Outperformance

Kunal Khanna: "Our volume growth has been 350 bps higher than the market, while the market volume growth as per MAT June was close to 1.5%, we have registered 4% plus."

Torrent Acquisition: Platform Creation, Limited Disclosure

Nikhil Chopra: "The transaction creates a diversified health care platform with deep capabilities in chronic and international CDMO segment."

International Business: Soft Q1, H2 Recovery Expected


Margins: Record Highs with Cost Discipline

Nikhil Chopra: "30.2%, our EBITDA margins are the best up till now what we have been reported."

CDMO & New Launches: Building the Pipeline


Guidance & Commitments

CommitmentSpecificsTimeline
Domestic revenue growth12-14% growth, 300-400 bps above marketFY26
CDMO revenue growth12-14% growth; H2 run rate ~INR130 croreFY26
International branded genericsHigh single-digit growthBy end of Q3 FY26
Gross marginMaintain at 67%FY26
EBITDA margin27-29%, aim for top percentile of rangeFY26
Operating cash flow75-78% of operating EBITDAFY26
Azmarda volumeReach 140,000 units per monthNext 3-4 months
ROW market launchesLaunch quantities of 8-10 molecules across 14-16 marketsQ4 FY26
CDMO new launches3-4 important new launchesNext 12-18 months
Ophthalmology rankingMove from 6th to top 59 months to a year

Key Metrics

MetricQ1 FY26
Revenue₹1,094 cr, +9% YoY
Domestic revenue₹678 cr, +14% YoY
International revenue₹416 cr, +2% YoY
Gross margin68.3%, +210 bps YoY from 66.2%
Operating EBITDA (excl. ESOP and one-off)₹330 cr, +13% YoY
Operating EBITDA margin (excl. ESOP and one-off)30.2%, +120 bps YoY from 29%
Net profit (excl. one-off)₹214 cr, +21% YoY
PAT margin (excl. one-off)19.6%
Domestic growth per IQVIA13%, vs industry 9%
Chronic portfolio growth per IQVIA15% YoY
Acute portfolio growth per IQVIA12% YoY
Ophthalmology portfolio growth per IQVIA19% YoY
CDMO revenue₹115 cr, +8% YoY
International Formulations revenue₹283 cr, -2% YoY from ₹290 cr
API revenue₹18 cr, +38% YoY
CDMO full-year growth guidance12% to 14%
Domestic full-year growth guidance300–400 bps above market growth
Full-year gross margin guidance67%
Full-year operating EBITDA margin guidance27% to 29%
Sporlac franchise size (MAT June 2025)₹146 cr, up from ₹70 cr in June 2022
Azmarda brand size₹75 cr
Razel franchise size (MAT June 2025)crossed ₹100 cr, up from ₹69 cr in June 2023
One-off merger scheme charges₹15 cr
Operating cash flow guidance (full year)75% to 78% of operating EBITDA